Summary
Project Summary Crohn’s disease (CD) and ulcerative colitis (UC) affect over 2 million individuals in the United States and are associated with considerable morbidity. Existing treatments achieve remission in fewer than 50% of patients. Further, despite achieving endoscopic remission, up to 30% of patients with CD or UC will relapse over the subsequent three years. Pathophysiologic mechanisms leading to relapse have not been well established. The central premise of our proposal is that despite endoscopic, there exists a local pro-inflammatory microbial milieu and transcriptional profile that f
